News & AnalysisDiCE Molecules attracts $60mDiCE Molecules, a biopharmaceutical company, has raised $60 million in Series C-1 financing.ByIris Dorbian24 August 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs